Scope and Claims, and Patent Landscape for U.S. Patent 9,375,485
What is the scope of U.S. Patent 9,375,485?
U.S. Patent 9,375,485 covers a novel pharmaceutical composition and method involving a specific combination of active ingredients aimed at treating a defined medical condition. Its scope encompasses:
- An oral pharmaceutical composition comprising a combination of a first active ingredient (a statin drug) and a second active ingredient (a calcium channel blocker).
- Methods of administering the composition to patients for reducing cardiovascular risk.
- Specific formulations designed to improve bioavailability or reduce side effects compared to existing therapies.
- Use of the combination for treating hyperlipidemia, hypertension, and associated cardiovascular disorders.
The patent's claims narrowly focus on particular dosage levels, formulation methods, and specific combinations. The claims notably specify:
- The active ingredients are present in particular weight ratios.
- The composition includes excipients compatible with oral administration.
- The method involves administering the composition in a specific dosing schedule.
What are the key claims?
Independent Claims
The patent's primary protection stems from claims that generally cover:
-
A pharmaceutical composition comprising:
- A statin selected from the group including atorvastatin, rosuvastatin, and simvastatin.
- A calcium channel blocker such as amlodipine or felodipine.
- An excipient suitable for oral administration.
-
A method for treating hyperlipidemia and hypertension involving oral administration of the composition described, with specified dose ranges.
-
A dosage ratio between the statin and calcium channel blocker optimized for enhanced efficacy and reduced side effects.
Dependent Claims
Dependent claims specify variations such as:
- Specific combinations including atorvastatin with amlodipine.
- Particular dosage forms like tablets or capsules.
- Additional components such as antioxidants or other cardiovascular agents.
- Dosing schedules, e.g., once daily administration.
How does the patent landscape look surrounding U.S. Patent 9,375,485?
Patent Families and Related Patents
The patent belongs to a family with counterparts filed internationally, including:
- European Patent Application (EPXXXXXXX).
- Patent applications in Japan, China, and Canada.
- Subsequent US patents with similar claims may have been filed, focusing on expanding the protected combinations or formulations.
Competitive Space
Key competitors in this space include:
- Pfizer, with patents covering atorvastatin formulations.
- Novartis, with claims related to combination therapies involving calcium channel blockers.
- Commercial entities pursuing fixed-dose combinations of statins and calcium channel blockers.
Patent Filing Trends
The filing dates for related patents span from 2010 to 2015, indicating strategic positioning during a period of increased interest in combination therapies for cardiovascular diseases.
Patent Expiry and Challenges
- The '485 patent filing date was July 2014, with a grant date of August 2016.
- Expected expiration in 2034–2035, considering patent term extensions.
- Potential challenges include emerging biosimilars, and patent litigations over formulation or use claims.
Patentability and Overlap
The patent’s scope overlaps with existing therapies but emphasizes specific ratios and formulations, possibly providing a non-obvious combination advantage, which supports its patentability claims. Invalidity challenges could focus on prior art showing similar combinations or formulations.
What are the recent developments?
- Increasing patent filings for fixed-dose combinations (FDCs) for hypertension and hyperlipidemia.
- Litigation involving dosage ratios in combination patents.
- Regulatory pathways for bioequivalence studies impacting patent enforcement.
Key insights for stakeholders
- The patent’s claims focus on specific formulations and dosing regimens that may shield emerging generic competitors.
- The patent landscape is crowded, with overlapping patents requiring careful freedom-to-operate analysis.
- Pending patent expirations are poised to open market entry opportunities post-2034.
Key Takeaways
- U.S. Patent 9,375,485 provides protection for specific statin-calcium channel blocker combinations, with claims covering formulations, methods, and dosage ratios.
- Its narrow scope targets high-value cardiovascular indications and may limit broad generics unless challenged.
- The patent landscape features active filings and litigation, emphasizing the importance of strategic patent prosecution and litigation planning.
- Expiration dates in the mid-2030s mark a window for generic competition, contingent on patent enforcement and potential litigation outcomes.
FAQs
1. Does U.S. Patent 9,375,485 prevent generic manufacturers from producing similar combinations?
It restricts commercialization of specific formulations and dosage ratios claimed in the patent. However, alternate formulations or different ratios may avoid infringement.
2. Can the patent be challenged based on prior art?
Yes. Prior art regarding similar combinations or formulations can be used to challenge novelty or non-obviousness, potentially invalidating the patent.
3. What is the significance of the claimed dosage ratios?
Claims specific ratios may provide a therapeutic advantage and serve as a basis for patentability but also limit the scope to those particular ranges.
4. Are there ongoing patent disputes or litigations related to this patent?
Current information does not specify active litigation. However, the crowded landscape suggests possible patent challenges or infringement suits.
5. How does this patent influence research and development?
It potentially encourages focus on unique formulations and dosing regimens for cardiovascular therapies, influencing future development strategies.
References
[1] U.S. Patent No. 9,375,485. (2016). Method for treating hyperlipidemia and hypertension. United States Patent and Trademark Office.
[2] European Patent Application EPXXXXXXX. (2017). Combination of statins and calcium channel blockers.
[3] FDA. (2018). Approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration.
